Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Notes Payables: 2014-2020

Historic Notes Payables for Larimar Therapeutics (LRMR) over the last 5 years, with Mar 2020 value amounting to $7.3 million.

  • Larimar Therapeutics' Notes Payables changed negligibly% to $7.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was $7.3 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $7.3 million for FY2019, which is 33.33% up from last year.
  • As of Q1 2020, Larimar Therapeutics' Notes Payables stood at $7.3 million, which was down 0.00% from $7.3 million recorded in Q4 2019.
  • Larimar Therapeutics' Notes Payables' 5-year high stood at $20.5 million during Q3 2018, with a 5-year trough of $1.3 million in Q3 2017.
  • For the 3-year period, Larimar Therapeutics' Notes Payables averaged around $11.4 million, with its median value being $7.3 million (2020).
  • The largest annual percentage gain for Larimar Therapeutics' Notes Payables in the last 5 years was 1,516.72% (2018), contrasted with its biggest fall of 72.72% (2018).
  • Quarterly analysis of 5 years shows Larimar Therapeutics' Notes Payables stood at $3.6 million in 2016, then spiked by 457.26% to $20.0 million in 2017, then slumped by 72.72% to $5.5 million in 2018, then skyrocketed by 33.33% to $7.3 million in 2019, then remained steady at $7.3 million in 2020.
  • Its last three reported values are $7.3 million in Q1 2020, $7.3 million for Q4 2019, and $7.3 million during Q3 2019.